Issue 30, 2007

Coordination chemistry and biology of chelators for the treatment of iron overload disorders

Abstract

Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally. Until this time most patients with Fe overload have had to endure long periods of subcutaneous infusions of the orally ineffective drug desferrioxamine (desferal) which has led to major problems with patient compliance. An effective Fe chelator must possess a number of properties for it to be able to complex Fe in vivo and be excreted intact. This Perspective will provide an overview of the current state of chelators for Fe overload; both those currently approved and those undergoing preclinical development.

Graphical abstract: Coordination chemistry and biology of chelators for the treatment of iron overload disorders

Article information

Article type
Perspective
Submitted
29 Mei 2007
Accepted
18 Jun 2007
First published
05 Jul 2007

Dalton Trans., 2007, 3214-3220

Coordination chemistry and biology of chelators for the treatment of iron overload disorders

P. V. Bernhardt, Dalton Trans., 2007, 3214 DOI: 10.1039/B708133B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements